.webp)
Monoclonal antibodies (mAbs) are a critical component of bioconjugates, directing cytotoxic payloads to target specifically diseased cells. Their specificity and selectivity are essential for optimizing the efficacy of bioconjugate therapies while minimizing their off-target effects.
Our Hyderabad facility serves as our dedicated mAb supplier, providing integrated mAb services from early-stage process development through GMP manufacturing. The facility has a proven track record of success, backed by dedicated project managers and functional teams who provide scientific guidance and ensure efficient program execution. By combining deep technical expertise with project-driven oversight, Hyderabad enables seamless technology transfer, consistent production, and reliable delivery of monoclonal antibodies for clinical and commercial bioconjugate programs.
